Compare NBTX & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | RBCAA |
|---|---|---|
| Founded | 2003 | 1974 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2018 | 1998 |
| Metric | NBTX | RBCAA |
|---|---|---|
| Price | $32.60 | $91.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $54.24 | N/A |
| AVG Volume (30 Days) | ★ 136.4K | 78.3K |
| Earning Date | 09-24-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 2.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $417,495,000.00 |
| Revenue This Year | N/A | $1.02 |
| Revenue Next Year | $50.69 | $4.64 |
| P/E Ratio | ★ N/A | $118.32 |
| Revenue Growth | N/A | ★ 8.50 |
| 52 Week Low | $19.14 | $63.97 |
| 52 Week High | $57.14 | $102.22 |
| Indicator | NBTX | RBCAA |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 47.01 |
| Support Level | $30.73 | $88.88 |
| Resistance Level | $35.17 | $94.06 |
| Average True Range (ATR) | 1.84 | 2.11 |
| MACD | 0.56 | 0.07 |
| Stochastic Oscillator | 72.25 | 25.12 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.